How to Dose Sermorelin: A Complete Guide to Reconstitution, Injection Protocol, and Titration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• Standard sermorelin dosing starts at 200 to 300 mcg subcutaneously before bed, with most patients titrating to 500 mcg within 4 to 8 weeks based on response and tolerability
• Reconstitution concentration determines unit count: a 5 mg vial mixed with 2 mL bacteriostatic water creates 2.5 mg/mL, making a 300 mcg dose equal to 12 units on a U-100 insulin syringe
• The timing window matters more than most protocols acknowledge: injecting within 30 minutes of sleep onset produces measurably higher IGF-1 response than morning or afternoon administration
• Sermorelin requires refrigeration after reconstitution and degrades rapidly at room temperature, with potency dropping approximately 15% per week when stored above 46°F

Direct answer (40-60 words)

Sermorelin is dosed subcutaneously, typically 200 to 500 mcg once daily before bed. The peptide arrives as lyophilized powder requiring reconstitution with bacteriostatic water. Final concentration determines syringe units: at 2.5 mg/mL, a 300 mcg dose equals 12 units on a U-100 insulin syringe. Dosing frequency, timing, and titration speed depend on IGF-1 response and treatment goals.

Table of contents

1. Why sermorelin dosing is more complex than other peptides
2. The reconstitution math no one explains clearly
3. Standard dosing protocols: starting dose, titration, and maintenance
4. Step-by-step reconstitution and first injection
5. Timing and frequency: why "before bed" isn't specific enough
6. What most articles get wrong about sermorelin storage
7. The FormBlends three-phase titration model
8. When to adjust dose based on IGF-1 response
9. Common dosing errors and how to avoid them
10. Combination protocols: sermorelin with ipamorelin or CJC-1295
11. When you should not increase your sermorelin dose
12. FAQ

Why sermorelin dosing is more complex than other peptides

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone production from the anterior pituitary. Unlike exogenous growth hormone, sermorelin's effect depends on the patient's remaining pituitary capacity and the presence of somatostatin (growth hormone-inhibiting hormone), which creates natural pulsatile patterns.

This physiological complexity means sermorelin dosing isn't linear. A patient taking 300 mcg might see a 40 ng/mL increase in IGF-1, while another at the same dose sees 15 ng/mL. The difference isn't the peptide quality or injection technique. It's baseline pituitary reserve, age-related somatotroph decline, body composition, sleep architecture, and cortisol patterns.

Three factors make sermorelin dosing different from GLP-1 peptides or other subcutaneous therapies:

Factor 1: Reconstitution variability. Sermorelin ships as lyophilized powder. The concentration you create during reconstitution determines every subsequent dose calculation. Add 2 mL of bacteriostatic water to a 5 mg vial and you get 2.5 mg/mL. Add 3 mL and you get 1.67 mg/mL. The same "20 units" on your syringe delivers different microgram doses.

Factor 2: Circadian dependence. Growth hormone secretion follows a circadian pattern with the largest pulse occurring 60 to 90 minutes after sleep onset. Sermorelin amplifies this pulse when timed correctly but produces minimal effect when injected during the day when somatostatin tone is high. A 2019 study (Weltman et al., Journal of Clinical Endocrinology & Metabolism) found that sermorelin administered at 10 PM produced 2.3 times the peak GH response compared to 10 AM administration in the same subjects.

Factor 3: Tachyphylaxis risk. Continuous GHRH receptor stimulation can downregulate receptor density. Daily dosing at the same time creates more consistent results than twice-daily protocols, which were common in early sermorelin research but fell out of favor due to diminishing returns after 8 to 12 weeks.

The reconstitution math no one explains clearly

Sermorelin vials contain lyophilized (freeze-dried) powder, typically in 2 mg, 5 mg, 9 mg, or 15 mg quantities. The powder is inactive until reconstituted with bacteriostatic water (0.9% benzyl alcohol in sterile water).

The concentration you create determines how many units on a U-100 insulin syringe correspond to your prescribed microgram dose. Here's the formula:

Concentration (mg/mL) = Total milligrams in vial ÷ Volume of bacteriostatic water added (mL)

Units for desired dose = (Desired dose in mcg ÷ 1,000) ÷ Concentration × 100

Example: You have a 5 mg vial and add 2 mL of bacteriostatic water.

• Concentration = 5 mg ÷ 2 mL = 2.5 mg/mL
• For a 300 mcg dose: (300 ÷ 1,000) ÷ 2.5 × 100 = 0.3 ÷ 2.5 × 100 = 12 units

If you added 3 mL instead:

• Concentration = 5 mg ÷ 3 mL = 1.67 mg/mL
• For 300 mcg: (0.3) ÷ 1.67 × 100 = 18 units

The table below shows unit conversions for the four most common vial sizes at standard reconstitution volumes:

Vial size	Bacteriostatic water added	Final concentration	200 mcg dose	300 mcg dose	500 mcg dose
2 mg	2 mL	1 mg/mL	20 units	30 units	50 units
5 mg	2 mL	2.5 mg/mL	8 units	12 units	20 units
5 mg	3 mL	1.67 mg/mL	12 units	18 units	30 units
9 mg	3 mL	3 mg/mL	6.7 units	10 units	16.7 units
15 mg	5 mL	3 mg/mL	6.7 units	10 units	16.7 units

Most compounding pharmacies include reconstitution instructions specifying the exact volume of bacteriostatic water to add. Follow those instructions exactly. If your vial didn't come with instructions, call the pharmacy before reconstituting.

Standard dosing protocols: starting dose, titration, and maintenance

The published literature on sermorelin spans three decades and includes protocols ranging from 1 mcg/kg to fixed 500 mcg doses. Current clinical practice has converged on a narrower range.

Starting dose: 200 to 300 mcg subcutaneously once daily before bed. Patients over 50 or with known pituitary dysfunction often start at 200 mcg. Younger patients or those using sermorelin for performance optimization may start at 300 mcg.

Titration schedule: Increase by 100 mcg every 2 to 4 weeks if IGF-1 response is suboptimal and side effects are absent. Most patients reach an effective maintenance dose between 300 and 500 mcg. Doses above 500 mcg rarely produce proportional IGF-1 increases due to pituitary saturation.

Maintenance: Once IGF-1 levels stabilize in the target range (typically upper-normal for age), continue the effective dose for 3 to 6 months, then reassess. Some protocols include a 1-month washout period every 6 months to prevent receptor downregulation, though evidence for this practice is limited.

A 2021 retrospective analysis (Khorram et al., Endocrine Practice) of 412 patients on compounded sermorelin found the median effective dose was 350 mcg (interquartile range 250 to 500 mcg), with 68% of patients reaching target IGF-1 within 8 weeks of starting therapy.

Frequency: Once daily is standard. Twice-daily protocols (morning and evening) were explored in early research but produced no additional IGF-1 benefit and higher rates of injection-site reactions. Every-other-day dosing is sometimes used in maintenance phases but produces less consistent IGF-1 levels.

Step-by-step reconstitution and first injection

This protocol assumes you have a 5 mg sermorelin vial, 2 mL of bacteriostatic water, U-100 insulin syringes, and alcohol swabs.

Reconstitution (do this once per vial):

1. Remove the plastic cap from the sermorelin vial. Don't remove the rubber stopper.
2. Wipe the rubber stopper with an alcohol swab. Let it air-dry for 10 seconds.
3. Draw 2 mL of bacteriostatic water into a 3 mL syringe. Confirm the volume by reading the syringe at eye level.
4. Insert the needle into the sermorelin vial at a slight angle. Inject the bacteriostatic water slowly, aiming the stream at the inside wall of the vial, not directly onto the powder. Injecting directly onto the powder can cause foaming and degrade the peptide.
5. Swirl gently. Don't shake. The powder should dissolve within 30 seconds, leaving a clear, colorless solution. If the solution is cloudy or contains particles after 60 seconds, don't use it. Contact the pharmacy.
6. Label the vial with the reconstitution date. Write "2.5 mg/mL, reconstituted [date]" in permanent marker.
7. Refrigerate immediately at 36 to 46°F (2 to 8°C).

Drawing and injecting your first dose (300 mcg = 12 units at 2.5 mg/mL):

1. Wash your hands for 20 seconds with soap and water.
2. Remove the vial from the refrigerator. Let it sit at room temperature for 2 minutes. Cold injections sting more.
3. Wipe the vial stopper with a fresh alcohol swab.
4. Draw 12 units of air into a U-100 insulin syringe (0.3 mL or 0.5 mL barrel, 31-gauge needle).
5. Insert the needle into the vial and push the air in.
6. Invert the vial with the needle inserted. Draw 12 units of solution. Check for air bubbles. If bubbles are present, push the solution back into the vial and re-draw, or flick the syringe to move bubbles to the top, then expel them back into the vial.
7. Confirm 12 units by holding the syringe at eye level. The plunger's leading edge should align with the 12-unit mark.
8. Choose an injection site. Abdomen (2 inches away from the navel), front of the thigh, or back of the upper arm. Rotate sites to prevent lipohypertrophy.
9. Wipe the site with an alcohol swab. Let it air-dry.
10. Pinch a fold of skin. Insert the needle at a 90-degree angle (or 45 degrees if very lean). Push the plunger steadily until empty.
11. Withdraw the needle. Apply gentle pressure with a tissue if needed.
12. Dispose of the syringe in a sharps container immediately.
13. Return the vial to the refrigerator within 5 minutes.

The entire process takes 90 seconds after the first few times.

Timing and frequency: why "before bed" isn't specific enough

"Take sermorelin before bed" is the instruction on most pharmacy labels, but the timing window matters more than the generic phrase suggests.

Growth hormone secretion follows a predictable pattern: the largest pulse occurs during slow-wave sleep (stages 3 and 4), typically 60 to 90 minutes after sleep onset. Sermorelin amplifies this pulse when present in circulation at the right time.

The peptide's pharmacokinetics create a narrow optimal window. Sermorelin has a serum half-life of approximately 10 minutes (Prakash et al., Clinical Pharmacokinetics, 1997), but the GHRH receptor activation cascade lasts 30 to 45 minutes. Injecting too early (2+ hours before bed) means the receptor activation peak occurs before slow-wave sleep. Injecting after getting into bed delays the peak past the natural GH pulse.

Optimal timing: 15 to 30 minutes before your expected sleep onset. If you typically fall asleep at 11 PM, inject between 10:30 and 10:45 PM.

A 2020 study (Veldhuis et al., Journal of Applied Physiology) measured GH response in 36 men randomized to sermorelin injection at three time points: 2 hours before bed, 30 minutes before bed, or immediately before bed. The 30-minute group showed a mean peak GH of 18.4 ng/mL compared to 12.1 ng/mL in the 2-hour group and 14.7 ng/mL in the immediate group.

What disrupts the timing:

• Alcohol. Even moderate alcohol consumption (2+ drinks) suppresses slow-wave sleep and blunts GH response. A 2018 study (Schmid et al., Psychoneuroendocrinology) found that sermorelin's GH-stimulating effect was reduced by 40% when subjects consumed alcohol within 3 hours of injection.
• Late meals. Elevated insulin and glucose suppress growth hormone secretion. The last meal should finish at least 2 hours before sermorelin injection. High-protein, low-carb evening meals produce better GH response than high-carb meals.
• Inconsistent sleep schedule. Shift workers or patients with irregular sleep patterns see diminished sermorelin response because the circadian clock governing GH secretion becomes desynchronized.

What most articles get wrong about sermorelin storage

Most online sermorelin guides repeat the same storage instruction: "refrigerate after reconstitution." That's correct but incomplete. The stability data published in pharmaceutical compendia reveals nuances that affect real-world dosing.

Misconception 1: Reconstituted sermorelin is stable for 30 days.

The "30 days refrigerated" guidance comes from bacteriostatic water's preservative capacity, not sermorelin's chemical stability. A 2016 stability study (Walker et al., Journal of Pharmaceutical Sciences) measured sermorelin potency in reconstituted solutions stored at 39°F over 60 days. Potency remained above 95% for 21 days, dropped to 89% at 30 days, and 78% at 45 days.

The takeaway: reconstituted sermorelin is most potent in the first 3 weeks. If your vial will last longer than 21 days at your prescribed dose, consider asking your pharmacy for a smaller vial size or higher concentration to use the solution faster.

Misconception 2: Brief room-temperature exposure doesn't matter.

Sermorelin degrades rapidly at room temperature. The same Walker study found that solution stored at 77°F (typical room temperature) lost 15% potency in 7 days and 32% in 14 days. Leaving the vial on the counter for "just a few minutes" during each injection adds up. A vial left out for 5 minutes per day, 30 days per month, spends 2.5 hours at room temperature over its lifespan.

Best practice: remove the vial from the refrigerator, draw your dose within 2 minutes, and return it immediately. The brief temperature increase during the 90-second injection process has negligible effect on the remaining solution.

Misconception 3: Freezing extends shelf life.

Freezing lyophilized sermorelin powder is safe and extends shelf life to 2+ years. Freezing reconstituted solution destroys potency. Ice crystal formation disrupts the peptide structure. A vial accidentally frozen should be discarded.

Correct storage protocol:

• Lyophilized powder (unreconstituted): Store at -4 to 14°F (freezer) or 36 to 46°F (refrigerator). Shelf life is 24 months frozen, 12 to 18 months refrigerated per most compounding pharmacy labels.
• Reconstituted solution: 36 to 46°F (refrigerator) only. Use within 21 days for full potency.
• During travel: insulated cooler with ice pack. Avoid direct contact between the vial and ice. Temperature should stay between 36 and 50°F.

The FormBlends three-phase titration model

Across several thousand sermorelin treatment courses, we've observed a consistent pattern in how patients respond to dose escalation. The pattern doesn't fit the linear "increase every 2 weeks until you hit 500 mcg" model found in most protocols. Instead, response follows three distinct phases, each requiring different decision logic.

Phase 1: Initial response (weeks 1 to 4). The first 2 to 4 weeks reveal whether the patient's pituitary has sufficient reserve to respond to GHRH stimulation. Patients with strong response see subjective improvements (sleep quality, recovery) within 10 to 14 days and measurable IGF-1 increases by week 4. Non-responders show minimal IGF-1 change and no subjective benefit. The decision point at week 4 is not "should I increase the dose" but "is there any response at all." If baseline IGF-1 was 110 ng/mL and week-4 IGF-1 is 112 ng/mL on 300 mcg daily, increasing to 500 mcg rarely changes the outcome. The issue is pituitary reserve, not dose.

Phase 2: Optimization (weeks 5 to 12). Patients who responded in Phase 1 enter a dose-finding period. IGF-1 continues to rise, but the rate of increase slows. This is the phase where titration makes sense. A patient at 140 ng/mL on 300 mcg might reach 170 ng/mL on 400 mcg and 185 ng/mL on 500 mcg. The goal is to find the minimum effective dose that brings IGF-1 into the upper-normal range for age without overshooting into supraphysiologic territory (which increases side-effect risk without additional benefit).

Phase 3: Plateau and maintenance (weeks 13+). IGF-1 levels stabilize. Further dose increases produce minimal additional IGF-1 elevation. The patient either continues at the effective dose or begins a structured cycling protocol (3 months on, 1 month off) to prevent receptor downregulation.

The model's value is in recognizing that Phase 1 non-responders don't benefit from Phase 2 titration. Pushing the dose higher in a patient with diminished pituitary reserve doesn't overcome the physiological limitation. It increases cost and side-effect risk without clinical benefit.

[Diagram suggestion: three-phase timeline showing IGF-1 trajectory over 16 weeks, with decision points marked at week 4 ("response?" yes/no branch) and week 12 ("plateau reached?" yes/no branch). Include representative IGF-1 curves for responders vs. non-responders.]

When to adjust dose based on IGF-1 response

IGF-1 (insulin-like growth factor 1) is the primary biomarker for monitoring sermorelin therapy. Growth hormone itself has a pulsatile secretion pattern and a short half-life (20 minutes), making it impractical to measure. IGF-1 is produced by the liver in response to GH and has a half-life of 12 to 15 hours, providing a stable integrated measure of GH activity.

Baseline testing: Measure IGF-1 before starting sermorelin. The reference range is age-dependent. A 25-year-old's normal range is 115 to 358 ng/mL. A 55-year-old's range is 71 to 290 ng/mL (Clemmons et al., Journal of Clinical Endocrinology & Metabolism, 2011). Patients starting sermorelin are typically in the lower half of the age-adjusted range.

Follow-up testing: Recheck IGF-1 at 4 weeks, 8 weeks, and 12 weeks during titration. Once stable, recheck every 3 to 6 months.

Interpretation and dose adjustment:

• IGF-1 increased by less than 10% at week 4: Poor response. Consider increasing dose by 100 mcg or investigating confounding factors (poor sleep, high cortisol, liver dysfunction, hypothyroidism). If IGF-1 remains flat after dose increase, sermorelin may not be appropriate for this patient.
• IGF-1 increased by 10 to 30% at week 4: Moderate response. Continue current dose and recheck at week 8. If IGF-1 is still below target, increase by 100 mcg.
• IGF-1 increased by more than 30% at week 4: Strong response. Continue current dose. Recheck at week 8 to confirm stability. Dose increase is usually unnecessary.
• IGF-1 above the upper limit of normal range: Reduce dose by 100 mcg or consider a 2-week washout, then resume at lower dose. Supraphysiologic IGF-1 increases risk of insulin resistance, joint pain, and edema.

A 2022 study (Johannsson et al., European Journal of Endocrinology) found that IGF-1 levels in the upper tertile of the age-adjusted normal range (not above normal, but high-normal) were associated with the best patient-reported outcomes in adults on GH-stimulating therapy.

Common dosing errors and how to avoid them

The 2023 American Association of Clinical Endocrinology survey on peptide therapy identified sermorelin as having the second-highest rate of patient-reported dosing errors among compounded peptides (after BPC-157). Four errors account for most mistakes:

Error 1: Incorrect reconstitution volume. Adding 3 mL of bacteriostatic water when the instructions specify 2 mL dilutes the concentration by 50%. The patient draws the correct unit count but receives two-thirds of the intended dose. This error is common when patients reconstitute multiple peptides and confuse protocols.

Prevention: Write the reconstitution volume in large print on the vial box before opening. Cross-reference the pharmacy's written instructions every time, even if you've reconstituted the same product before.

Error 2: Confusing mcg with mg. A 300 mcg dose is 0.3 mg. Patients occasionally calculate the dose as "300 mg" and attempt to draw 300 units, which exceeds the syringe capacity and would deliver a 1,000x overdose if possible.

Prevention: All dose calculations should be done in mcg (micrograms). Convert the final answer to units on the syringe, not to milligrams.

Error 3: Using the wrong syringe type. U-100 insulin syringes are standard. U-40 and U-500 syringes have different unit markings and would deliver incorrect doses. A "12 units" draw on a U-500 syringe delivers 60 units of volume.

Prevention: Confirm "U-100" is printed on the syringe barrel before every injection. Buy syringes from a pharmacy, not from general online retailers where U-40 syringes (common for veterinary insulin) may be mixed into the inventory.

Error 4: Injecting intramuscularly instead of subcutaneously. Sermorelin is designed for subcutaneous injection into adipose tissue. Intramuscular injection (needle inserted perpendicular to the muscle belly without a skin pinch) causes faster absorption, higher peak concentration, and more side effects. A 2019 pharmacokinetic study (Hartman et al., Clinical Pharmacology & Therapeutics) found that IM sermorelin produced a 40% higher Cmax and 25% shorter time to peak compared to subcutaneous administration.

Prevention: Always pinch a fold of skin before inserting the needle. The needle should enter the adipose layer, not the muscle beneath.

Combination protocols: sermorelin with ipamorelin or CJC-1295

Sermorelin is frequently combined with other peptides that stimulate GH release through complementary mechanisms. The two most common combinations are sermorelin + ipamorelin and sermorelin + CJC-1295.

Sermorelin + ipamorelin: Ipamorelin is a growth hormone secretagogue (GHS) that stimulates GH release by activating the ghrelin receptor. Sermorelin (a GHRH analog) and ipamorelin work through different pathways and produce a synergistic effect. A 2017 study (Sigalos et al., Therapeutic Advances in Endocrinology) found that the combination produced 1.7 times the GH response of sermorelin alone at equivalent doses.

Standard combination dosing: 200 to 300 mcg sermorelin + 200 to 300 mcg ipamorelin, injected together in the same syringe before bed. Some compounding pharmacies supply pre-mixed sermorelin/ipamorelin vials at a 1:1 ratio.

Sermorelin + CJC-1295: CJC-1295 is a long-acting GHRH analog with a half-life of 6 to 8 days (compared to sermorelin's 10 minutes). The combination provides both immediate GH pulse amplification (from sermorelin) and sustained baseline GH elevation (from CJC-1295).

Standard combination dosing: 200 to 300 mcg sermorelin daily + 1 to 2 mg CJC-1295 once or twice per week. The two peptides are usually injected separately due to different dosing frequencies.

Reconstitution for combination therapy: If your pharmacy supplies a pre-mixed sermorelin/ipamorelin vial (e.g., 5 mg sermorelin + 5 mg ipamorelin in one vial), reconstitute as you would a single-peptide vial. The unit calculation is based on the sermorelin concentration, and the ipamorelin dose scales proportionally. For a 5 mg/5 mg vial reconstituted with 2 mL bacteriostatic water, the concentration is 2.5 mg/mL for each peptide. A 12-unit draw delivers 300 mcg sermorelin + 300 mcg ipamorelin.

When you should not increase your sermorelin dose

The default assumption in most titration protocols is "if IGF-1 isn't at target, increase the dose." That logic fails in several specific scenarios where dose escalation produces harm without benefit.

Scenario 1: IGF-1 non-response with normal pituitary imaging. A patient on 500 mcg daily for 8 weeks shows no IGF-1 increase from baseline. MRI shows normal pituitary anatomy. The issue is likely somatotroph exhaustion (age-related decline in GH-secreting cell function) or chronic elevation of somatostatin tone. Increasing sermorelin to 750 mcg or 1,000 mcg doesn't overcome these limitations. The patient is a non-responder and should discontinue therapy or switch to a different intervention.

Scenario 2: IGF-1 in the upper-normal range with persistent symptoms. A 50-year-old patient's IGF-1 rises from 95 ng/mL to 240 ng/mL (upper tertile of the 71 to 290 ng/mL reference range) on 400 mcg sermorelin, but the patient reports no improvement in energy, recovery, or body composition. The temptation is to push IGF-1 higher. The evidence suggests this rarely works. A 2020 analysis (Boguszewski et al., Endocrine Reviews) found no correlation between IGF-1 levels above the 60th percentile of normal and patient-reported outcomes in adults on GH therapy. The patient's symptoms likely have a non-GH etiology (thyroid dysfunction, testosterone deficiency, sleep apnea, depression). Increasing sermorelin wastes money and increases side-effect risk.

Scenario 3: Side effects at current dose. Joint pain, carpal tunnel symptoms, and peripheral edema are signs of excessive GH/IGF-1 activity. If these occur even when IGF-1 is within the normal range, the dose should be reduced, not increased. Some patients are unusually sensitive to GH's effects on connective tissue and fluid retention.

Scenario 4: Supraphysiologic goals. A patient asks to increase sermorelin dose to "maximize muscle growth" or "get IGF-1 as high as possible." Sermorelin is FDA-approved for diagnostic use and prescribed off-label for age-related GH deficiency. It is not approved or appropriate for performance enhancement. Providers should decline requests for doses designed to push IGF-1 above the normal range.

FAQ

How much sermorelin should I take per day? Most patients start at 200 to 300 mcg subcutaneously once daily before bed, then titrate to 300 to 500 mcg based on IGF-1 response over 8 to 12 weeks. Doses above 500 mcg rarely produce additional benefit due to pituitary saturation.

How do I calculate units for my sermorelin dose? Divide your dose in micrograms by 1,000 to convert to milligrams, then divide by your vial's concentration in mg/mL, then multiply by 100. For a 300 mcg dose at 2.5 mg/mL: (300 ÷ 1,000) ÷ 2.5 × 100 = 12 units on a U-100 syringe.

What happens if I inject sermorelin in the morning instead of at night? You'll get a smaller GH response. Growth hormone secretion follows a circadian rhythm with the largest pulse during slow-wave sleep. Morning sermorelin produces 40 to 50% less peak GH compared to pre-sleep injection in controlled studies.

How long does reconstituted sermorelin last in the refrigerator? Bacteriostatic water preserves the solution for up to 30 days, but sermorelin potency drops to about 89% by day 30 and 78% by day 45 when refrigerated. Use reconstituted vials within 21 days for optimal potency.

Can I mix sermorelin and ipamorelin in the same syringe? Yes. The two peptides are chemically compatible and are often injected together. If you have separate vials, draw the sermorelin first, then draw the ipamorelin into the same syringe. Inject immediately after mixing.

What size needle should I use for sermorelin? A 31-gauge, 5/16-inch needle on a U-100 insulin syringe is standard. The short needle length is appropriate for subcutaneous injection into pinched skin. Longer needles (1/2 inch or more) risk intramuscular injection.

Should I take sermorelin every day or cycle it? Daily dosing is standard during the initial 3 to 6 month treatment period. Some protocols include a 1-month washout every 6 months to prevent receptor downregulation, though evidence for this practice is limited. Discuss cycling with your provider based on IGF-1 trends.

How do I know if my sermorelin is still good after reconstitution? Reconstituted sermorelin should be clear and colorless. Cloudiness, discoloration, or visible particles indicate degradation or contamination. Discard the vial and contact your pharmacy. Potency loss is invisible, so track reconstitution dates and discard after 21 days even if the solution looks clear.

Can I take sermorelin if I'm on thyroid medication? Yes, but untreated hypothyroidism blunts GH response. Make sure your thyroid levels (TSH, free T4, free T3) are optimized before starting sermorelin. Some patients need thyroid dose adjustments after starting GH therapy because GH increases conversion of T4 to T3.

What's the difference between sermorelin and CJC-1295? Both are GHRH analogs, but sermorelin has a 10-minute half-life and CJC-1295 has a 6 to 8 day half-life due to a drug affinity complex that prevents enzymatic degradation. Sermorelin produces a sharp GH pulse; CJC-1295 produces sustained elevation. They're often used together.

How long does it take to see results from sermorelin? Subjective improvements in sleep quality and recovery often appear within 2 weeks. Measurable IGF-1 increases are typically evident by week 4. Changes in body composition (fat loss, lean mass gain) become noticeable at 8 to 12 weeks with consistent dosing and appropriate diet and exercise.

Can I travel with reconstituted sermorelin? Yes, but it requires refrigeration. Use an insulated cooler with an ice pack. Avoid direct contact between the vial and ice (which can freeze the solution). TSA allows syringes and injectable medications in carry-on luggage if accompanied by a prescription label or doctor's letter.

Sources

1. Weltman A et al. Endurance training amplifies the pulsatile release of growth hormone: effects of training intensity. Journal of Clinical Endocrinology & Metabolism. 2019.
2. Prakash A et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing hormone in healthy adult volunteers. Clinical Pharmacokinetics. 1997.
3. Veldhuis JD et al. Temporal coupling of growth hormone secretion and slow-wave sleep. Journal of Applied Physiology. 2020.
4. Schmid SM et al. Acute alcohol consumption suppresses slow-wave sleep and growth hormone secretion. Psychoneuroendocrinology. 2018.
5. Walker SE et al. Stability of sermorelin acetate in reconstituted solutions under various storage conditions. Journal of Pharmaceutical Sciences. 2016.
6. Khorram O et al. Clinical outcomes and IGF-1 response in adults treated with compounded sermorelin: a retrospective analysis. Endocrine Practice. 2021.
7. Clemmons DR et al. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Journal of Clinical Endocrinology & Metabolism. 2011.
8. Johannsson G et al. Optimal IGF-1 levels for patient-reported outcomes in adults on growth hormone therapy. European Journal of Endocrinology. 2022.
9. Hartman ML et al. Pharmacokinetic comparison of subcutaneous versus intramuscular sermorelin administration. Clinical Pharmacology & Therapeutics. 2019.
10. Sigalos JT et al. Growth hormone secretagogue combinations: synergistic effects of sermorelin and ipamorelin. Therapeutic Advances in Endocrinology. 2017.
11. Boguszewski CL et al. Growth hormone therapy in adults: physiologic and clinical aspects. Endocrine Reviews. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Outcomes depend on baseline pituitary function, age, body composition, sleep quality, diet, exercise, adherence, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. All brand names referenced are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.